Global Chronic Gingivostomatitis Treatment Market, by Diagnosis (Physical Examination, Microbial Culture, Biopsy, and Others), by Treatment (Non-steroidal Anti-inflammatory Drugs, Antiviral, Antibacterial, and Others), by End User (Hospitals & Clinics, Academic & Research, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 12,922.5 million in 2020 and is expected to exhibit a CAGR of 6.5% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Affordable treatment for herpetic gingivostomatitis is expected to boost the market growth. For instance, according to the Western Journal of Emergency Medicine, an article - Cost of Routine Herpes Simplex Virus Infection Visits to U.S. ED 2006-2013, published in 2018, reports that emergency department (ED) cost around US$ 71.02 for the herpetic gingivostomatitis treatment during 2006-2013 in the U.S.
Global Chronic Gingivostomatitis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 63.14 million infected individuals worldwide as of December 2, 2020.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Moreover, the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs for chronic gingivostomatitis, which is expected to hamper the market growth in the near future.
Browse 35 Market Data Tables and 30 Figures spread through 180 Pages and in-depth TOC on “Chronic Gingivostomatitis Treatment Market – by Diagnosis (Physical Examination, Microbial Culture, Biopsy, and Others), by Treatment (Non-steroidal Anti-inflammatory Drugs, Antiviral, Antibacterial, and Others), by End User (Hospitals & Clinics, Academic & Research, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027”
To know the latest trends and insights prevalent in the global chronic gingivostomatitis treatment market, click the link below:
Rising cases of chronic gingivostomatitis is boosting growth of the market. For instance, according to the Royal Children's Hospital Melbourne, an article published in February 2020 stated that herpetic gingivostomatitis is the most common specific clinical manifestation, which accounts for 15-30% of all the oral cases.
Key Takeaways of the Global Chronic Gingivostomatitis Treatment Market:
- The global chronic gingivostomatitis treatment market is expected to exhibit a CAGR of 6.5% during the forecast period, owing to rising incidence of chronic gingivostomatitis. For instance, according to the National Center for Biotechnology Information (NCBI), an article - Acute gingivostomatitis in children: Epidemiology in the emergency department, pain, and use of codeine before its restriction, published in February 2019, stated that acute gingivostomatitis is a relatively frequent reason for pediatric emergency department (PED) visits.
- Among diagnosis, physical examination segment held a dominant position in the chronic gingivostomatitis treatment market in 2019, owing to cost effectivity and availability of physicians
- Among treatment, non-steroidal anti-inflammatory drugs segment held a dominant position in the chronic gingivostomatitis treatment market in 2019, owing to its effective indication for the prevention and treatment of chronic gingivostomatitis
- Among end user, hospitals & clinics segment held a dominant position in the chronic gingivostomatitis treatment market in 2019, owing to rising visits to emergency department. For instance, according to the Western Journal of Emergency Medicine, an article - Cost of Routine Herpes Simplex Virus Infection Visits to U.S. ED 2006-2013, published in 2018, reports that there were 115,726 number of patient visits with primary diagnosis during 2006-2013 in the U.S.
- Key players operating in the global chronic gingivostomatitis treatment market include Pfizer Inc., Taj Pharmaceutical limited, Ciron pharma, Johnson & Johnson, GlaxoSmithKline PLC, Merck & CO., Inc., Novartis AG, F. Hoffman La Roche AG, Eli Lily and Company, and AstraZeneca Plc.
